Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| KROS | PRESS-RELEASE | neutral | 3/10 | Keros Therapeutics reported Q2 2026 net loss of $28.7M (EPS -$1.45), missing consensus EPS of -$1.24 and zero revenue vs | Aug 3, 2026 |
| NATR | PRESS-RELEASE | neutral | 2/10 | Nature's Sunshine appointed Janine Weber as EVP and President, North America, effective August 10, 2026. Weber brings ov | Aug 3, 2026 |
| AIM | PRESS-RELEASE | neutral | 4/10 | AIM ImmunoTech announced that the final subject received their last dose in the Phase 2 DURIPANC trial of Ampligen for m | Aug 3, 2026 |
| PTHS | PRESS-RELEASE | neutral | 1/10 | Pelthos Therapeutics, Inc. announced it will report its Q2 2026 results on August 13, 2026. | Aug 3, 2026 |
| CADL | PRESS-RELEASE | neutral | 2/10 | Candel Therapeutics announced that an abstract on aglatimagene besadenovec in localized prostate cancer was accepted for | Aug 3, 2026 |
| DSGN | PRESS-RELEASE | bullish | 5/10 | Design Therapeutics reported Q2 2026 net loss of $0.32 per share, beating consensus of -$0.36 by 11%, and highlighted po | Aug 3, 2026 |
| SPRY | PRESS-RELEASE | neutral | 1/10 | ARS Pharmaceuticals, Inc. announced it will host a conference call on August 13 to discuss its Q2 2026 results. | Aug 3, 2026 |
| RGNX | PRESS-RELEASE | neutral | 1/10 | REGENXBIO Inc. announced it will host a conference call on August 6 to discuss its Q2 2026 results. | Aug 3, 2026 |
| ALT | PRESS-RELEASE | bullish | 6/10 | Altimmune initiated the PERFORMA Phase 3 registrational trial of pemvidutide in MASH, a key milestone following positive | Aug 3, 2026 |
| LNTH | PRESS-RELEASE | bullish | 7/10 | Lantheus Holdings has entered into a definitive agreement to be acquired by Curium US Holdings LLC for $102.50 per share | Aug 3, 2026 |
| HELP | PRESS-RELEASE | bullish | 5/10 | Helus Pharma appointed Michael Halstead as CEO effective immediately. Halstead was President of Intra-Cellular Therapies | Aug 3, 2026 |
| BNTX | PRESS-RELEASE | neutral | 4/10 | BioNTech announced the appointment of Guido Oelkers, Ph.D., as the new CEO, effective by February 1, 2027, succeeding co | Aug 3, 2026 |
| FBLG | PRESS-RELEASE | neutral | 4/10 | FibroBiologics reported Q2 2026 EPS of -$0.66, beating consensus of -$0.93 by 29%, but remains pre-revenue with $3.5M ca | Jul 31, 2026 |
| GRML | PRESS-RELEASE | neutral | 3/10 | Greenland Mines announced the departure of its support vessel Argus from Reykjavik to the Skaergaard Project, marking th | Jul 31, 2026 |
| ELUT | PRESS-RELEASE | neutral | 1/10 | Elutia Inc. announced it will report its Q2 2026 results on August 13, 2026. | Jul 31, 2026 |
| RADX | PRESS-RELEASE | mixed | 6/10 | Radiopharm Theranostics reported positive Phase 2b results for RAD 101 (93% primary endpoint achievement) and plans a Ph | Jul 31, 2026 |
| HOWL | PRESS-RELEASE | mixed | 5/10 | Werewolf Therapeutics reported Q2 2026 net income of $3.7M ($0.08 EPS), a significant swing from a net loss of $18.0M in | Jul 31, 2026 |
| TENX | PRESS-RELEASE | neutral | 5/10 | Tenax Therapeutics reported Q2 2026 net loss of $17.8M ($0.35/share), slightly beating consensus of -$0.36. Cash positio | Jul 31, 2026 |
| TLX | PRESS-RELEASE | neutral | 1/10 | Telix Pharmaceuticals Limited announced it will host a conference call on August 20, 2026 to discuss its half-year 2026 | Jul 30, 2026 |
| MYGN | PRESS-RELEASE | bearish | 7/10 | Myriad Genetics reported Q2 2026 revenue of $190.7M (11% YoY decline, 7.4% below consensus) and adjusted EPS of -$0.25 ( | Jul 30, 2026 |
| SXTP | PRESS-RELEASE | bearish | 6/10 | Sixty Degrees Pharmaceuticals announced a private placement of 574,713 shares (or pre-funded warrants) with Series A and | Jul 30, 2026 |
| CAPR | PRESS-RELEASE | bearish | 7/10 | The FDA's Cellular, Tissue and Gene Therapies Advisory Committee voted 9-3 against evidence supporting Deramiocel's effe | Jul 30, 2026 |
| IRON | PRESS-RELEASE | bullish | 7/10 | Disc Medicine reported Q2 2026 net loss of $59.5M ($1.54/share), beating consensus of -$1.77 by 13%. The key catalyst is | Jul 30, 2026 |
| REGN | PRESS-RELEASE | bullish | 7/10 | Regeneron reported Q2 2026 non-GAAP EPS of $14.29, a 40.1% beat vs consensus of $10.20, on total revenue of $4.29B (+17% | Jul 30, 2026 |
| AGIO | PRESS-RELEASE | bullish | 7/10 | Agios reported Q2 2026 revenue of $44.7M, up 259% YoY and 68% above consensus of $26.7M, driven by the AQVESME launch in | Jul 30, 2026 |
| PVLA | PRESS-RELEASE | neutral | 2/10 | Palvella Therapeutics announced that its Chief Scientific Officer, Dr. Jeffrey Martini, has been selected to provide pub | Jul 30, 2026 |
| PHAT | PRESS-RELEASE | bearish | 6/10 | Phathom reported Q2 2026 net revenue of $74.3M, up 88% YoY and above the $72.7M consensus, driven by strong VOQUEZNA pre | Jul 30, 2026 |
| QNTM | PRESS-RELEASE | neutral | 3/10 | Quantum BioPharma settled CAD$123,487.43 in debt by issuing 30,948 Class B shares at CAD$3.99 per share to arm's length | Jul 30, 2026 |
| INO | PRESS-RELEASE | bearish | 7/10 | Inovio Pharmaceuticals priced a $20M underwritten public offering of 21,052,632 shares and warrants to purchase up to 42 | Jul 29, 2026 |
| VNDA | PRESS-RELEASE | neutral | 1/10 | Vanda Pharmaceuticals Inc. announced it will report its Q2 2026 results on August 5, 2026. | Jul 29, 2026 |